

Indikationen zur Insulintherapie bei Typ-2-Diabetes – Wahl des Therapie-Regimes nach individuellen Kriterien

Thorsten Siegmund
aus BDI aktuell 7/2007

- 1** Hauner H. **The costs of diabetes mellitus and its complications in Germany.** Dtsch Med Wochenschr 2006; 131: 240-242
- 2** Liebl A, Neiss A, Spannheimer A. et al.. **Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany - results from the CODE-2 study.** Exp Clin Endocrinol Diabetes 2002; 110: 10-16
- 3** Kahn SE. **The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus.** Am J Med 2000; 108: 2-8
- 4** Glaser B, Cerasi E. **Early intensive insulin treatment for induction of long-term glycaemic control in type 2 diabetes.** Diabetes Obes Metab 1999; 1: 67-74
- 5** Polonsky S, Given BD, Hirsch LJ. et al.. **Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus.** N Engl J Med 1988; 318: 1231-1239
- 6** U.K. prospective diabetes study 16. **Overview over 6 years therapy of type II diabetes: a progressive disease.** Diabetes 1995; 44: 1249-1258
- 7** Shah V, Pratley RE. **The DREAM Trial: Using Ramipril and Rosiglitazone to Prevent Diabetes.** Curr Diab Rep 2007; 7: 53-55
- 8** Baggio LL, Drucker DJ. **Therapeutic approaches to preserve islet mass in type 2 diabetes.** Annu Rev Med 2006; 57: 265-281
- 9** Haak T, Tiengo A, Draeger E. et al.. **Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.** Diabetes Obes Metab 2005; 7: 56-64
- 10** Rosenstock J, Dailey G, Massi-Benedetti M. et al.. **Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes.** Diabetes Care 2005; 28: 950-955
- 11** Riddle MC, Rosenstock J, Gerich J. et al.. **The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.** Diabetes Care 2003; 26: 3080-3086
- 12** Hermansen K, Davies M, Derezinski T. et al.. **A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes.** Diabetes Care 2006; 29: 1269-1274
- 13** Ritzel RA, Veldhuis JD, Butler PC. **Glucose stimulates pulsatile insulin secretion from human pancreatic islets by increasing secretory burst mass: dose-response relationships.** J Clin Endocrinol Metab 2003; 88: 742-747
- 14** Fritsche A, Schweitzer MA, Haring HU. et al.. **Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.** Ann Intern Med 2003; 138: 952-959

15 Raskin P, Ellen E, Hollander P. et al.. **Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.** Diabetes Care 2005; 28: 260-265

16 Janka HU, Plevé G, Riddle MC. et al.. **Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.** Diabetes Care 2005; 28: 254-259

17 Monnier L, Lapinski H, Colette C. **Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).** Diabetes Care 2003; 26: 881-885

18 Monnier L, Dunseath GJ, Colette C. et al.. **The Loss of Postprandial Glycemic Control Precedes Stepwise Deterioration of Fasting With Worsening Diabetes.** Diabetes Care 2007; 30: 263-269

19 Siegmund T, Weber S, Blankenfeld H. et al.. **Comparison of insulin glargine versus NPH insulin in people with Type 2 Diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin.** Submitted

20 Gaede P, Vedel P, Larson N. et al.. **Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.** N Engl J Med 2003; 348: 383-393